{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:37:07Z","timestamp":1792791427797,"version":"4.5.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.intimp.2022.109205","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T19:48:40Z","timestamp":1662580120000},"page":"109205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["MicroRNA expression profiles of peripheral blood and mononuclear cells in myasthenia gravis: A systematic review"],"prefix":"10.1016","volume":"112","author":[{"given":"Amene","family":"Saghazadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2022.109205_b0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJM197701202960301","article-title":"Myasthenia gravis: study of humoral immune mechanisms by passive transfer to mice","volume":"296","author":"Toyka","year":"1977","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2022.109205_b0010","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.51.4.933-a","article-title":"Antibody to acetylcholine receptor in myasthenia gravis Prevalence, clinical correlates, and diagnostic value","volume":"51","author":"Lindstrom","year":"1998","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.intimp.2022.109205_b0015","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent","year":"1985","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.intimp.2022.109205_b0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.intimp.2022.109205_b0025","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.intimp.2022.109205_b0030","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109205_b0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109205_b0040","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"The Lancet Neurology"},{"issue":"1","key":"10.1016\/j.intimp.2022.109205_b0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in Myasthenia Gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC neurology"},{"issue":"9","key":"10.1016\/j.intimp.2022.109205_b0050","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.autrev.2013.03.006","article-title":"Novel future therapeutic options in myasthenia gravis","volume":"12","author":"Dalakas","year":"2013","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2022.109205_b0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.autrev.2007.01.001","article-title":"Therapeutic options in autoimmune myasthenia gravis","volume":"6","author":"Garc\u00eda-Carrasco","year":"2007","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2022.109205_b0060","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: Association of British Neurologists\u2019 management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract. Neurol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109205_b0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaut.2009.02.012","article-title":"MicroRNA in autoimmunity and autoimmune diseases","volume":"32","author":"Pauley","year":"2009","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.intimp.2022.109205_b0070","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2174\/138920209788185252","article-title":"MicroRNA: implications for Alzheimer disease and other human CNS disorders","volume":"10","author":"Maes","year":"2009","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.intimp.2022.109205_b0075","first-page":"1","article-title":"MicroRNA machinery in Parkinson\u2019s disease: a platform for neurodegenerative diseases","author":"Saghazadeh","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.intimp.2022.109205_b0080","doi-asserted-by":"crossref","unstructured":"E. Sonkoly, M. St\u00e5hle, A. Pivarcsi, MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation, Elsevier, pp. 131\u2013140.","DOI":"10.1016\/j.semcancer.2008.01.005"},{"issue":"10","key":"10.1016\/j.intimp.2022.109205_b0085","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrd3179","article-title":"Targeting microRNAs in cancer: rationale, strategies and challenges","volume":"9","author":"Garzon","year":"2010","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.intimp.2022.109205_b0090","doi-asserted-by":"crossref","unstructured":"H. Xie, L. Sun, H.F. Lodish, Targeting microRNAs in obesity, (2009).","DOI":"10.1517\/14728220903190707"},{"issue":"18","key":"10.1016\/j.intimp.2022.109205_b0095","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.109205_b0100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fnins.2020.00507","article-title":"Emerging Roles of Dysregulated MicroRNAs in Myasthenia Gravis","volume":"14","author":"Wang","year":"2020","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.intimp.2022.109205_b0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000494802","article-title":"MicroRNA-653 Inhibits Thymocyte Proliferation and Induces Thymocyte Apoptosis in Mice with Autoimmune Myasthenia Gravis by Downregulating TRIM9","volume":"26","author":"Cao","year":"2019","journal-title":"NeuroImmunoModulation"},{"issue":"6","key":"10.1016\/j.intimp.2022.109205_b0110","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.autrev.2018.01.008","article-title":"Analysis of microRNA expression in the thymus of Myasthenia Gravis patients opens new research avenues","volume":"17","author":"Cron","year":"2018","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2022.109205_b0115","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10875-012-9834-5","article-title":"MiR-320a is downregulated in patients with myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1","volume":"33","author":"Cheng","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.intimp.2022.109205_b0120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fimmu.2020.00151","article-title":"Estrogen Receptor Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating microRNAs","volume":"11","author":"Fiorillo","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109205_b0125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2022.109205_b0130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jneuroim.2016.01.003","article-title":"Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis","volume":"292","author":"Punga","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2022.109205_b0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2018.10.003","article-title":"Circulating microRNA plasma profile in MuSK+ myasthenia gravis","volume":"325","author":"Sabre","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2022.109205_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104388","article-title":"MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicine","volume":"148","author":"Cavalcante","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.intimp.2022.109205_b0145","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3892\/ijmm.2017.2853","article-title":"Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis","volume":"39","author":"Cao","year":"2017","journal-title":"Int. J. Mol. Med."},{"issue":"5","key":"10.1016\/j.intimp.2022.109205_b0150","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/WCO.0000000000000596","article-title":"Myasthenia gravis: from autoantibodies to therapy","volume":"31","author":"Mantegazza","year":"2018","journal-title":"Curr. Opin. Neurol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109205_b0155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nyas.13510","article-title":"Circulating microRNAs as potential biomarkers in myasthenia gravis patients","volume":"1412","author":"Punga","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2022.109205_b0160","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.intimp.2022.109205_b0165","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.neulet.2013.09.014","article-title":"Altered expression of miR-146a in myasthenia gravis","volume":"555","author":"Lu","year":"2013","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.intimp.2022.109205_b0170","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.intimp.2012.07.003","article-title":"Altered let-7 expression in Myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells","volume":"14","author":"Jiang","year":"2012","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109205_b0175","doi-asserted-by":"crossref","first-page":"e91927","DOI":"10.1371\/journal.pone.0091927","article-title":"Analysis of serum miRNA profiles of myasthenia gravis patients","volume":"9","author":"Nogales-Gadea","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2022.109205_b0180","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3389\/fimmu.2019.00539","article-title":"Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis","volume":"10","author":"Cron","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109205_b0185","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jneuroim.2018.05.003","article-title":"Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis","volume":"321","author":"Sabre","year":"2018","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109205_b0190","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/acn3.24","article-title":"Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker","volume":"1","author":"Punga","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.intimp.2022.109205_b0195","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/518942","article-title":"Clinical Study of Effects of Jian Ji Ning, a Chinese Herbal Medicine Compound Preparation, in Treating Patients with Myasthenia Gravis via the Regulation of Differential MicroRNAs Expression in Serum","volume":"2014","author":"Jiang","year":"2014","journal-title":"Evidence-based complementary and alternative medicine : eCAM"},{"issue":"3","key":"10.1016\/j.intimp.2022.109205_b0200","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10238-015-0358-1","article-title":"Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis","volume":"16","author":"Zhang","year":"2016","journal-title":"Clin. Experim. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.109205_b0205","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/cei.12265","article-title":"Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis","volume":"176","author":"Wang","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2022.109205_b0210","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jns.2015.06.019","article-title":"Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients","volume":"356","author":"Punga","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2022.109205_b0215","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1684\/ecn.2015.0367","article-title":"Disease-specific signature of serum miR-20b and its targets IL-8 and IL-25, in myasthenia gravis patients","volume":"26","author":"Chunjie","year":"2015","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.intimp.2022.109205_b0220","doi-asserted-by":"crossref","first-page":"5573469","DOI":"10.1155\/2021\/5573469","article-title":"Expression and Clinical Significance of miR-146a and Tumor Necrosis Factor Receptor-Associated Factor 6 (TRAF6) in Myasthenia Gravis Patient Serum","volume":"2021","author":"Yan","year":"2021","journal-title":"Biomed. Res. Int."},{"issue":"4","key":"10.1016\/j.intimp.2022.109205_b0225","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1002\/jcb.27838","article-title":"The long non-coding RNA MALAT-1 functions as a competing endogenous RNA to regulate MSL2 expression by sponging miR-338-3p in myasthenia gravis","volume":"120","author":"Kong","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.intimp.2022.109205_b0230","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clim.2015.12.009","article-title":"MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10","volume":"164","author":"Liu","year":"2016","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2022.109205_b0235","first-page":"1774","article-title":"miR-15b is Downregulated in Myasthenia Gravis Patients and Directly Regulates the Expression of Interleukin-15 (IL-15) in Experimental Myasthenia Gravis Mice","volume":"21","author":"Shi","year":"2015","journal-title":"Med. Sci. Monitor Int. Med. J. Experim. Clin. Res."},{"key":"10.1016\/j.intimp.2022.109205_b0240","doi-asserted-by":"crossref","first-page":"9595718","DOI":"10.1155\/2016\/9595718","article-title":"miR-20b Inhibits T Cell Proliferation and Activation via NFAT Signaling Pathway in Thymoma-Associated Myasthenia Gravis","volume":"2016","author":"Xin","year":"2016","journal-title":"Biomed. Res. Int."},{"issue":"2","key":"10.1016\/j.intimp.2022.109205_b0245","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/acn3.692","article-title":"miR-30e-5p as predictor of generalization in ocular myasthenia gravis","volume":"6","author":"Sabre","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.intimp.2022.109205_b0250","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fimmu.2020.00142","article-title":"miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids","volume":"11","author":"Bortone","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109205_b0255","article-title":"MiR-181a regulates CD4(+) T cell activation and differentiation by targeting IL-2 in the pathogenesis of myasthenia gravis","author":"Liu","year":"2019","journal-title":"Eur. J. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109205_b0260","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.imbio.2016.06.012","article-title":"A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients","volume":"221","author":"Barzago","year":"2016","journal-title":"Immunobiology"},{"issue":"3","key":"10.1016\/j.intimp.2022.109205_b0265","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/mus.26785","article-title":"Plasma exosomal miR-106a-5p expression in myasthenia gravis","volume":"61","author":"Xu","year":"2020","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.intimp.2022.109205_b0270","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5507\/bp.2019.009","article-title":"Upregulation of MiR150-5p in generalized myasthenia gravis patients is associated with decreased serum levels of il-17 and increased serum levels of IL-10","volume":"164","author":"Ao","year":"2020","journal-title":"Biomed. Pap."},{"issue":"4","key":"10.1016\/j.intimp.2022.109205_b0275","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.trsl.2011.01.007","article-title":"MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases","volume":"157","author":"Dai","year":"2011","journal-title":"Transl. Res."},{"issue":"13","key":"10.1016\/j.intimp.2022.109205_b0280","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3390\/jcm10132748","article-title":"MicroRNA Expression Changes in Kidney Transplant: Diagnostic Efficacy of miR-150-5p as Potential Rejection Biomarker, Pilot Study","volume":"10","author":"Alfaro","year":"2021","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.109205_b0285","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/mus.25493","article-title":"Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance-based measures: A pilot study","volume":"56","author":"Westerberg","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.intimp.2022.109205_b0290","doi-asserted-by":"crossref","unstructured":"C.A. Ju\u017awik, S.D. S, Y. Zhang, N. Paradis-Isler, A. Sylvester, A. Amar-Zifkin, C. Douglas, B. Morquette, C.S. Moore, A.E. Fournier, microRNA dysregulation in neurodegenerative diseases: A systematic review, Progress in neurobiology 182 (2019) 101664.","DOI":"10.1016\/j.pneurobio.2019.101664"},{"key":"10.1016\/j.intimp.2022.109205_b0295","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13229-015-0040-1","article-title":"Hypomethylation of miR-142 promoter and upregulation of microRNAs that target the oxytocin receptor gene in the autism prefrontal cortex","volume":"6","author":"Mor","year":"2015","journal-title":"Molecular autism"},{"key":"10.1016\/j.intimp.2022.109205_b0300","doi-asserted-by":"crossref","first-page":"14143","DOI":"10.1038\/srep14143","article-title":"MicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine-induced epilepsy\u2013comparison with human epileptic samples","volume":"5","author":"Roncon","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2022.109205_b0305","doi-asserted-by":"crossref","first-page":"15904","DOI":"10.1038\/s41598-017-16041-w","article-title":"Comparative analysis of cytokine\/chemokine regulatory networks in patients with hippocampal sclerosis (HS) and focal cortical dysplasia (FCD)","volume":"7","author":"Srivastava","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2022.109205_b0310","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.brainres.2018.08.035","article-title":"Simultaneous miRNA and mRNA transcriptome profiling of glioblastoma samples reveals a novel set of OncomiR candidates and their target genes","volume":"1700","author":"Gulluoglu","year":"2018","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.109205_b0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-019-1590-5","article-title":"Analysis of miRNA signatures in CSF identifies upregulation of miR-21 and miR-146a\/b in patients with multiple sclerosis and active lesions","volume":"16","author":"Mu\u00f1oz-San Mart\u00edn","year":"2019","journal-title":"J. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.intimp.2022.109205_b0320","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s12035-016-9764-y","article-title":"Differential Expression and Significance of Circulating microRNAs in Cerebrospinal Fluid of Acute Encephalitis Patients Infected with Japanese Encephalitis Virus","volume":"54","author":"Goswami","year":"2017","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109205_b0325","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1038\/s41598-017-02969-6","article-title":"Cerebrospinal fluid microRNAs are potential biomarkers of temporal lobe epilepsy and status epilepticus","volume":"7","author":"Raoof","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.intimp.2022.109205_b0330","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1160\/TH16-08-0606","article-title":"Distinctive expression signatures of serum microRNAs in ischaemic stroke and transient ischaemic attack patients","volume":"117","author":"Wu","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"5\u20136","key":"10.1016\/j.intimp.2022.109205_b0335","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000488365","article-title":"Diagnosis of Hyperacute and Acute Ischaemic Stroke: The Potential Utility of Exosomal MicroRNA-21-5p and MicroRNA-30a-5p","volume":"45","author":"Wang","year":"2018","journal-title":"Cerebrovascular diseases (Basel, Switzerland)"},{"issue":"6","key":"10.1016\/j.intimp.2022.109205_b0340","doi-asserted-by":"crossref","first-page":"e13022","DOI":"10.1111\/acel.13022","article-title":"MiR-21-5p\/dual-specificity phosphatase 8 signalling mediates the anti-inflammatory effect of haem oxygenase-1 in aged intracerebral haemorrhage rats","volume":"18","author":"Ouyang","year":"2019","journal-title":"Aging Cell"},{"key":"10.1016\/j.intimp.2022.109205_b0345","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.brainres.2016.07.015","article-title":"miR-21-5p alleviates leakage of injured brain microvascular endothelial barrier in vitro through suppressing inflammation and apoptosis","volume":"1650","author":"Ge","year":"2016","journal-title":"Brain Res."},{"key":"10.1016\/j.intimp.2022.109205_b0350","first-page":"1871","article-title":"Exosomes from MiR-21-5p-Increased Neurons Play a Role in Neuroprotection by Suppressing Rab11a-Mediated Neuronal Autophagy In Vitro After Traumatic Brain Injury","volume":"25","author":"Li","year":"2019","journal-title":"Medical Sci. Monitor Int. Med. J. Experim. Clin. Res."},{"key":"10.1016\/j.intimp.2022.109205_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116935","article-title":"Gastrodin combined with rhynchophylline inhibits cerebral ischaemia-induced inflammasome activation via upregulating miR-21-5p and miR-331-5p","volume":"239","author":"Zhang","year":"2019","journal-title":"Life Sci."},{"issue":"13","key":"10.1016\/j.intimp.2022.109205_b0360","doi-asserted-by":"crossref","first-page":"9358","DOI":"10.1074\/jbc.C600321200","article-title":"STAT3 regulates cytokine-mediated generation of inflammatory helper T cells","volume":"282","author":"Yang","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.intimp.2022.109205_b0365","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2022.109205_b0370","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eplepsyres.2018.05.001","article-title":"Targeting of microRNA-21-5p protects against seizure damage in a kainic acid-induced status epilepticus model via PTEN-mTOR","volume":"144","author":"Tang","year":"2018","journal-title":"Epilepsy Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.109205_b0375","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2019.03.019","article-title":"LncRNA FTX inhibits hippocampal neuron apoptosis by regulating miR-21-5p\/SOX7 axis in a rat model of temporal lobe epilepsy","volume":"512","author":"Li","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2022.109205_b0380","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/acn3.152","article-title":"Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b","volume":"2","author":"Ingwersen","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109205_b0385","doi-asserted-by":"crossref","first-page":"170","DOI":"10.5607\/en20046","article-title":"Upregulation of miR-20b Protects Against Cerebral Ischemic Stroke by Targeting Thioredoxin Interacting Protein (TXNIP)","volume":"30","author":"Yang","year":"2021","journal-title":"Experim. Neurobiol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109205_b0390","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.gene.2015.08.043","article-title":"Integrative computational mRNA-miRNA interaction analyses of the autoimmune-deregulated miRNAs and well-known Th17 differentiation regulators: An attempt to discover new potential miRNAs involved in Th17 differentiation","volume":"572","author":"Honardoost","year":"2015","journal-title":"Gene"},{"issue":"1pt2","key":"10.1016\/j.intimp.2022.109205_b0395","doi-asserted-by":"crossref","first-page":"e826","DOI":"10.1111\/j.1365-2567.2009.03089.x","article-title":"Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis","volume":"128","author":"Mu","year":"2009","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.intimp.2022.109205_b0400","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25) Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.109205_b0405","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","article-title":"Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses","volume":"22","author":"Sakaguchi","year":"2004","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109205_b0410","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clim.2004.04.005","article-title":"Increase of circulating CD4+CD25+ T cells in myasthenia gravis patients with stability and thymectomy","volume":"112","author":"Sun","year":"2004","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109205_b0415","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-11-3900","article-title":"Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis","volume":"105","author":"Balandina","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2022.109205_b0420","doi-asserted-by":"crossref","unstructured":"Y. Singh, O.A. Garden, F. Lang, B.S. Cobb, MicroRNA-15b\/16 Enhances the Induction of Regulatory T Cells by Regulating the Expression of Rictor and mTOR, Journal of immunology (Baltimore, Md. : 1950) 195(12) (2015) 5667\u20135677.","DOI":"10.4049\/jimmunol.1401875"},{"key":"10.1016\/j.intimp.2022.109205_b0425","doi-asserted-by":"crossref","unstructured":"R. Liu, X. Ma, L. Chen, Y. Yang, Y. Zeng, J. Gao, W. Jiang, F. Zhang, D. Li, B. Han, R. Han, R. Qiu, W. Huang, Y. Wang, J. Hao, MicroRNA-15b Suppresses Th17 Differentiation and Is Associated with Pathogenesis of Multiple Sclerosis by Targeting O-GlcNAc Transferase, J. Immunol. (Baltimore, Md. : 1950) 198(7) (2017), 2626\u20132639.","DOI":"10.4049\/jimmunol.1601727"},{"issue":"12","key":"10.1016\/j.intimp.2022.109205_b0430","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1089\/dna.2016.3349","article-title":"Upregulated Expression of microRNA-16 Correlates with Th17\/Treg Cell Imbalance in Patients with Rheumatoid Arthritis","volume":"35","author":"Wu","year":"2016","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.intimp.2022.109205_b0435","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fnmol.2018.00288","article-title":"Dysregulation of MicroRNAs and Target Genes Networks in Peripheral Blood of Patients With Sporadic Amyotrophic Lateral Sclerosis","volume":"11","author":"Liguori","year":"2018","journal-title":"Front. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.intimp.2022.109205_b0440","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1038\/s41467-020-17655-x","article-title":"A blood miRNA signature associates with sporadic Creutzfeldt-Jakob disease diagnosis","volume":"11","author":"Norsworthy","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2022.109205_b0445","first-page":"1","article-title":"Differential expression and significance of miRNAs in plasma extracellular vesicles of patients with Parkinson\u2019s disease","author":"Xie","year":"2020","journal-title":"Int. J. Neurosci."},{"issue":"4","key":"10.1016\/j.intimp.2022.109205_b0450","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3233\/JAD-170343","article-title":"A 9-microRNA Signature in Serum Serves as a Noninvasive Biomarker in Early Diagnosis of Alzheimer\u2019s Disease","volume":"60","author":"Guo","year":"2017","journal-title":"J. Alzheimer\u2019s disease : JAD"},{"key":"10.1016\/j.intimp.2022.109205_b0455","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2147\/OTT.S59871","article-title":"Micro-ribonucleic acid expression profiling and bioinformatic target gene analyses in laryngeal carcinoma","volume":"7","author":"Lu","year":"2014","journal-title":"OncoTargets Therapy"},{"issue":"8","key":"10.1016\/j.intimp.2022.109205_b0460","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1007\/s13277-014-1970-5","article-title":"Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer","volume":"35","author":"Liu","year":"2014","journal-title":"Tumour Biol. J. Int. Soc. Oncodevelopm. Biol. Med."},{"issue":"20","key":"10.1016\/j.intimp.2022.109205_b0465","doi-asserted-by":"crossref","first-page":"15350","DOI":"10.18632\/oncotarget.24601","article-title":"Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma","volume":"9","author":"Moshiri","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.intimp.2022.109205_b0470","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/abbs\/gmz164","article-title":"Exosomal miRNA profiling before and after surgery revealed potential diagnostic and prognostic markers for lung adenocarcinoma","volume":"52","author":"Xue","year":"2020","journal-title":"Acta Biochim. Biophy. Sin."},{"issue":"27","key":"10.1016\/j.intimp.2022.109205_b0475","doi-asserted-by":"crossref","first-page":"41575","DOI":"10.18632\/oncotarget.9491","article-title":"Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study","volume":"7","author":"Cao","year":"2016","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.intimp.2022.109205_b0480","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21144954","article-title":"Deep Sequencing of Small RNAs from Neurosurgical Extracellular Vesicles Substantiates miR-486-3p as a Circulating Biomarker that Distinguishes Glioblastoma from Lower-Grade Astrocytoma Patients","volume":"21","author":"Hallal","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2022.109205_b0485","first-page":"672","article-title":"MicroRNA signatures associated with lymph node metastasis in intramucosal gastric cancer, Modern pathology : an official journal of the United States and Canadian Academy of Pathology","volume":"34","author":"Kim","year":"2021","journal-title":"Inc"},{"key":"10.1016\/j.intimp.2022.109205_b0490","doi-asserted-by":"crossref","unstructured":"F.R. Tuncturk, I. Akalin, L. Uzun, T. Zenginkinet, Comparison of miRNA expressions among benign, premalignant and malignant lesions of the larynx: could they be transformation biomarkers?, Journal of otolaryngology - head & neck surgery = Le Journal d\u2019oto-rhino-laryngologie et de chirurgie cervico-faciale 50(1) (2021) 14.","DOI":"10.1186\/s40463-021-00497-y"},{"issue":"2","key":"10.1016\/j.intimp.2022.109205_b0495","first-page":"141","article-title":"Matrine induced G0\/G1 arrest and apoptosis in human acute T-cell lymphoblastic leukemia (T-ALL) cells","volume":"18","author":"Tetik Vardarl\u0131","year":"2018","journal-title":"Bosnian J. Basic Med. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2022.109205_b0500","first-page":"1817","article-title":"Effects of miR-106b-3p on cell proliferation and epithelial-mesenchymal transition, and targeting of ZNRF3 in esophageal squamous cell carcinoma","volume":"43","author":"Qiao","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.intimp.2022.109205_b0505","doi-asserted-by":"crossref","unstructured":"H. Liu, Y. Liu, P. Sun, K. Leng, Y. Xu, L. Mei, P. Han, B. Zhang, K. Yao, C. Li, J. Bai, B. Cui, Colorectal cancer-derived exosomal miR-106b-3p promotes metastasis by down-regulating DLC-1 expression, Clin. Sci. (London, England : 1979) 134(4) (2020) 419\u2013434.","DOI":"10.1042\/CS20191087"},{"key":"10.1016\/j.intimp.2022.109205_b0510","doi-asserted-by":"crossref","unstructured":"F. Mannavola, G. Pezzicoli, M. Tucci, DLC-1 down-regulation via exosomal miR-106b-3p exchange promotes CRC metastasis by the epithelial-to-mesenchymal transition, Clinical science (London, England : 1979) 134(8) (2020) 955\u2013959.","DOI":"10.1042\/CS20200181"},{"issue":"6","key":"10.1016\/j.intimp.2022.109205_b0515","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2021.12110","article-title":"Downregulation of miR-106b-3p increases sensitivity to cisplatin in esophageal cancer cells by targeting TGM3","volume":"23","author":"Zhu","year":"2021","journal-title":"Mol. Med. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2022.109205_b0520","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000381283","article-title":"Comprehensive Analysis of Serum microRNAs in Autoimmune Pancreatitis","volume":"91","author":"Hamada","year":"2015","journal-title":"Digestion"},{"issue":"7","key":"10.1016\/j.intimp.2022.109205_b0525","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1074\/jbc.M116.769893","article-title":"Extracellular MicroRNA Signature of Human Helper T Cell Subsets in Health and Autoimmunity","volume":"292","author":"Torri","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.intimp.2022.109205_b0530","doi-asserted-by":"crossref","first-page":"e0174585","DOI":"10.1371\/journal.pone.0174585","article-title":"MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sj\u00f6gren\u2019s syndrome","volume":"12","author":"Chen","year":"2017","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.intimp.2022.109205_b0535","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1212\/NXI.0000000000000450","article-title":"Thymectomy lowers the myasthenia gravis biomarker miR-150-5p","volume":"5","author":"Molin","year":"2018","journal-title":"Neurol. (R) Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.intimp.2022.109205_b0540","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3389\/fgene.2020.00442","article-title":"Red Blood Cells as Potential Repositories of MicroRNAs in the Circulatory System","volume":"11","author":"Sun","year":"2020","journal-title":"Front. Genet."},{"issue":"7","key":"10.1016\/j.intimp.2022.109205_b0545","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1537-2995.2010.02585.x","article-title":"Differential profiling of human red blood cells during storage for 52 selected microRNAs","volume":"50","author":"Kannan","year":"2010","journal-title":"Transfusion"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922006890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922006890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:42:54Z","timestamp":1761586974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922006890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":109,"alternative-id":["S1567576922006890"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109205","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MicroRNA expression profiles of peripheral blood and mononuclear cells in myasthenia gravis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109205","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109205"}}